Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- High Court Turns Down Iressa Compensation Appeal
November 16, 2011
- 7-Drug Rule Should Be Relaxed or Eliminated to Promote GE Name Prescribing: Dr Adachi of CSIMC
November 16, 2011
- Mr Sawai of JGA Opposes Reduction in NHI Prices of First Generics
November 16, 2011
- PAFSC Committee Recommends Classification of Isoconazole as Class 1 OTC Drug
November 15, 2011
- Merck Withdraws MAA for Sitagliptin, Pioglitazone Combination
November 15, 2011
- Former Health Minister Masuzoe Raises Drug Re-Pricing Issues Over TPP
November 14, 2011
- 2007’s “Emergency Proposal” for Distribution Reform Needs Review: Health Ministry Councilor Mr Takeda
November 11, 2011
- Discontinuation of Vaccination Following Death due to Unknown Cause Cannot Be Considered: David Salisbury, UK Director for Vaccines and Immunization
November 11, 2011
- MHLW Calls for Package Insert Revision for Bisphosphonates
November 11, 2011
- PMDA Draws Up "Global Vision" to Establish World Class Position
November 10, 2011
- MHLW Proposes Raising GE Dispensing Rates to Receive Upper Premiums for GE Dispensing Systems
November 10, 2011
- Mr Kobayashi of Kyokai Kenpo Proposes Measures to Promote GE Drug Use
November 10, 2011
- Applications for “Regulatory Strategy Consultation” Increasing Rapidly: Mr Isobe of PMDA
November 10, 2011
- Promote “Category-based” Negotiations Instead of Package Deals: Mr Hasegawa
November 10, 2011
- PAFSC Committee Approves Extension of Reexamination Period for DSP’s Lonasen
November 9, 2011
- MHLW Announces Add’l Indications Eligible for Applications Based on Info in Public Domain
November 9, 2011
- 1st PAFSC Committee Recommends Approval for Products Including Eisai’s Lunesta
November 8, 2011
- MHLW Announces Additional Indications for 3 APIs Following Prior Assessments
November 7, 2011
- CSIMC Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 4, 2011
- CSIMC Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 4, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…